Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus

NCT03948347 · Unknown status

Last updated 2026-05-28

This clinical trial is testing whether the medication liraglutide can help reduce the risk of new stroke events in people with type 2 diabetes who have recently experienced a minor ischemic stroke or a high-risk transient ischemic attack.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 1,708 people Planned (estimated).

Who can join Ages 50+ · all sexes

Timeline Started 2019-06 · est. completion 2024-06

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT03948347 ↗

Description as written by the study sponsor.

The purpose of this study is to assess the safety and efficacy of glucagon-like peptide-1 (GLP-1) analogue liraglutide in the treatment of acute minor stroke (National Institute of Health stroke scale, NIHSS ≤ 3) or high-risk transient ischemic attack (TIA) (ABCD2 score ≥ 4 ) patients with type 2 diabetes mellitus.

Treatments tested

Liraglutide also known as Victoza Drug

The treatment arm will receive the starting dose of liraglutide of 0.6 mg/d subcutaneously once daily, and the dose will be increased to 1.8 mg/d in two weeks, and then continue to administrate this dose for 90 days.

Main thing measured	Percentage of patients with the 90-day new stroke events (ischemic or hemorrhagic)
Sponsor	First Affiliated Hospital of Jinan University
Conditions studied	Ischemic Stroke, Transient Ischemic Attack, Type 2 Diabetes Mellitus
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03948347 ↗